Advertisement
Screener

Insight Molecular Diagnostics Inc. (IMDX) Segment Reporting Other Item Amount

2.8 / 5 stars · 68/120 Roast Me

Insight Molecular Diagnostics Inc. Segment Reporting Other Item Amount

Insight Molecular Diagnostics Inc. (IMDX) reported Segment Reporting Other Item Amount of $52.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Notes › Segment Reporting

us-gaap:SegmentReportingOtherItemAmount · last filed 2026-08-10

  • Insight Molecular Diagnostics Inc. segment reporting other item amount for the quarter ending 2026-06-30 was $52.00K, a 11.86% decline year-over-year.
  • Insight Molecular Diagnostics Inc. segment reporting other item amount for the quarter ending 2026-03-31 was $109.00K, a 37.71% decline year-over-year.
  • Insight Molecular Diagnostics Inc. segment reporting other item amount for the quarter ending 2025-12-31 was $485.00K.
  • Insight Molecular Diagnostics Inc. segment reporting other item amount for the quarter ending 2025-09-30 was -$97.00K.
  • Insight Molecular Diagnostics Inc. segment reporting other item amount for fiscal 2025 was $633.00K, a 681.48% increase from fiscal 2024.
  • Insight Molecular Diagnostics Inc. segment reporting other item amount for fiscal 2024 was $81.00K, a 92.30% decline from fiscal 2023.
  • Insight Molecular Diagnostics Inc. segment reporting other item amount for fiscal 2023 was $1.05M.
Period endSegment Reporting Other Item Amount 3 monthSegment Reporting Other Item Amount 3 month as first filedSegment Reporting Other Item Amount 6 monthSegment Reporting Other Item Amount 6 month as first filedSegment Reporting Other Item Amount 9 monthSegment Reporting Other Item Amount 12 monthSegment Reporting Other Item Amount 12 month as first filed
2026-06-30$52.00K
10-Q · filed 2026-08-10
$161.00K
10-Q · filed 2026-08-10
$646.00K
derived: sum of 3 quarters · filed 2026-08-10
$549.00K
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31$109.00K
10-Q · filed 2026-05-13
$594.00K
derived: sum of 2 quarters · filed 2026-05-13
$497.00K
derived: sum of 3 quarters · filed 2026-05-13
$556.00K
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$485.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$388.00K
derived: sum of 2 quarters · filed 2026-03-26
$447.00K
derived: sum of 3 quarters · filed 2026-08-10
$633.00K
10-K · filed 2026-03-26
2025-09-30-$97.00K
10-Q · filed 2025-11-10
-$38.00K
derived: sum of 2 quarters · filed 2026-08-10
$148.00K
10-Q · filed 2025-11-10
$88.00K
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30$59.00K
10-Q · filed 2026-08-10
$66.00K
10-Q · filed 2025-08-11
$234.00K
10-Q · filed 2026-08-10
$246.00K
10-Q · filed 2025-08-11
$185.00K
derived: sum of 3 quarters · filed 2026-08-10
$184.00K
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$175.00K
10-Q · filed 2026-05-13
$375.00K
10-Q · filed 2025-05-12
$126.00K
derived: sum of 2 quarters · filed 2026-05-13
$125.00K
derived: sum of 3 quarters · filed 2026-05-13
$169.00K
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31-$49.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
-$50.00K
derived: sum of 2 quarters · filed 2026-03-26
-$6.00K
derived: sum of 3 quarters · filed 2026-03-26
$81.00K
10-K · filed 2026-03-26
$666.00K
10-K · filed 2025-03-24
2024-09-30-$1.00K
10-Q · filed 2025-11-10
$43.00K
derived: sum of 2 quarters · filed 2025-11-10
$130.00K
10-Q · filed 2025-11-10
2024-06-30$44.00K
10-Q · filed 2025-08-11
$131.00K
10-Q · filed 2025-08-11
2024-03-31$158.00K
10-Q · filed 2025-05-12
2023-12-31$1.05M
10-K · filed 2025-03-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
BIOMERICA INC (BMRA)United States$0.011B
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
Cardio Diagnostics Holdings, Inc. (CDIO)United States$0.006B
VOLITIONRX LTD (VNRX)$0.003B-0.64
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92